Gregory Y.H. Lip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory Y.H. Lip has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Foo Leong Li-Saw-Hee
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
2 shared publicationsAndrew D. Blann
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK
1 shared publicationC Lydakis
University Department of Medicine, City Hospital, Birmingham, UK
1 shared publicationC. Lydakis
University Department of Medicine, City Hospital, Birmingham, UK
1 shared publicationCharalampos Lydakis
University Department of Medicine, City Hospital, Birmingham, UK
1 shared publicationD.GAreth Beevers
1 shared publication
Latest Publications
- 1 July 1998
- Published by Elsevier in International Journal of Cardiology
- Vol. 65 (2) , 187-192
Atrial fibrillation amongst the Indo-Asian general practice population
- 1 July 1998
- Published by Elsevier in International Journal of Cardiology
- Vol. 65 (2) , 187-192
Atrial fibrillation amongst the Indo-Asian general practice population
- 1 July 1998
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 16 (7) , 913-916
Does hypertension confer a hypercoagulable state?
Although the blood vessels are exposed to high pressures in hypertension, the main complications of hypertension (stroke and myocardial infarction) are paradoxically thrombotic rather than haemorrhagic. In keeping with Virchow's triad, patients with hypertension do demonstrate abnormalities of vessel wall (endothelial dysfunction or damage), blood constituents (abnormal levels of haemostatic factors, platelet activation and fibrinolysis) and blood flow (rheology and flow reserve), suggesting that hypertension does confer a prothrombotic or hypercoagulable state. These abnormalities appear to be related to target organ damage and long-term prognosis and are altered by treatment. The observation that satisfactory blood pressure reduction with non-drug intervention and with various classes of antihypertensive drugs does not lead to an equal reduction in heart attacks and strokes may be due in part to unfavourable effects on the hypercoagulable state in hypertension. Antihypertensive agents with particular benefits in reducing this hypercoagulable state would be likely to have additional advantages in reducing the occurrence of stroke and other thromboembolic events. J Hypertens 16:913–916 © 1998 Lippincott-Raven Publishers.
- 1 July 1998
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 16 (7) , 913-916
Does hypertension confer a hypercoagulable state?
Although the blood vessels are exposed to high pressures in hypertension, the main complications of hypertension (stroke and myocardial infarction) are paradoxically thrombotic rather than haemorrhagic. In keeping with Virchow's triad, patients with hypertension do demonstrate abnormalities of vessel wall (endothelial dysfunction or damage), blood constituents (abnormal levels of haemostatic factors, platelet activation and fibrinolysis) and blood flow (rheology and flow reserve), suggesting that hypertension does confer a prothrombotic or hypercoagulable state. These abnormalities appear to be related to target organ damage and long-term prognosis and are altered by treatment. The observation that satisfactory blood pressure reduction with non-drug intervention and with various classes of antihypertensive drugs does not lead to an equal reduction in heart attacks and strokes may be due in part to unfavourable effects on the hypercoagulable state in hypertension. Antihypertensive agents with particular benefits in reducing this hypercoagulable state would be likely to have additional advantages in reducing the occurrence of stroke and other thromboembolic events. J Hypertens 16:913–916 © 1998 Lippincott-Raven Publishers.
- Open Access
- 1 June 1998
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 91 (6) , 381-391
Microalbuminuria and cardiovascular risk
The term 'microalbuminuria' has been introduced to describe a measurable increase in urine albumin excretion, which is still within normal total urine protein excretion levels. Many data suggest that microalbuminuria is of value as an index of vascular damage, especially in hypertension and diabetes, and there is increasing information on its associations with traditional cardiovascular risk factors and its prognostic value. The association between microalbuminuria and peripheral markers of endothelial damage or dysfunction, such as von Willebrand factor, suggests the possibility that microalbuminuria may be a simple, cheap and easy index of endothelial abnormalities in cardiovascular disease. Nevertheless, further information on the value of microalbuminuria in other atherosclerotic vascular complications, such as ischaemic heart disease, stroke and peripheral artery disease is still needed.
- 1 June 1998
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 91 (6) , 381-391
Open AccessMicroalbuminuria and cardiovascular risk
The term 'microalbuminuria' has been introduced to describe a measurable increase in urine albumin excretion, which is still within normal total urine protein excretion levels. Many data suggest that microalbuminuria is of value as an index of vascular damage, especially in hypertension and diabetes, and there is increasing information on its associations with traditional cardiovascular risk factors and its prognostic value. The association between microalbuminuria and peripheral markers of endothelial damage or dysfunction, such as von Willebrand factor, suggests the possibility that microalbuminuria may be a simple, cheap and easy index of endothelial abnormalities in cardiovascular disease. Nevertheless, further information on the value of microalbuminuria in other atherosclerotic vascular complications, such as ischaemic heart disease, stroke and peripheral artery disease is still needed.
- 1 September 1997
- Published by Elsevier in International Journal of Cardiology
- Vol. 61 (2) , 171-174
The detection of endothelial dysfunction in patients with essential hypertension
- 1 September 1997
- Published by Elsevier in International Journal of Cardiology
- Vol. 61 (2) , 171-174
The detection of endothelial dysfunction in patients with essential hypertension
- 1 August 1997
- Published by Elsevier in Coronary Health Care
- Vol. 1 (3) , 130-137
Diet, lifestyle and blood pressure
- 1 August 1997
- Published by Elsevier in Coronary Health Care
- Vol. 1 (3) , 130-137
Diet, lifestyle and blood pressure
- 1 January 1997
- Published by Taylor & Francis in Blood Pressure
- Vol. 6 (6) , 368-371
An unusual cause of palpitations requiring atrioventricular node ablation and pacemaker therapy.
Lydakis C, Hollinrake K, Lip GYH. An unusual cause of palpitations requiring atrioventricular node ablation and pacemaker therapy. We report the unique case of a patient who complained of palpitations resistant to many antiarrhythmic treatment strategies, finally requiring treatment with atrioventricular node ablation and pacemaker implantation. A pheochromocytoma was eventually diagnosed, 16 years after the onset of her symptoms.
- 1 January 1997
- Published by Taylor & Francis in Blood Pressure
- Vol. 6 (6) , 368-371
An unusual cause of palpitations requiring atrioventricular node ablation and pacemaker therapy.
Lydakis C, Hollinrake K, Lip GYH. An unusual cause of palpitations requiring atrioventricular node ablation and pacemaker therapy. We report the unique case of a patient who complained of palpitations resistant to many antiarrhythmic treatment strategies, finally requiring treatment with atrioventricular node ablation and pacemaker implantation. A pheochromocytoma was eventually diagnosed, 16 years after the onset of her symptoms.